47 Paul Tudor Jones II Lilly(Eli) Trades
Paul Tudor Jones II's position in Lilly(Eli) is currently worth $32.2M. That's 0.16% of their equity portfolio (123rd largest holding). The first Lilly(Eli) trade was made in Q2 2013. Since then Paul Tudor Jones II bought shares 39 more times and sold shares on 35 occasions. The stake costed the investor $20.6M, netting the investor a gain of 56% so far.
News about Lilly(Eli) & Co and Paul Tudor Jones II
Eli Lilly Has A Solid Upside Now After Its Q3 Earnings
Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin analogs. LLY posted a 54% YoY reve...
Eli Lilly and : Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
… -Metabolic Medicine, Boehringer Ingelheim Pharmaceuticals , Inc. "Building … side effects of prescription drugs to the FDA. … 2023 Boehringer Ingelheim and...
Alzheimer’s disease market expected to reach $14B globally in 2030
Driven by novel drugs from Biogen (BIIB) and Eli Lilly (LLY), the Alzheimer’s disease market will hit $13.7B in 2030, according to a new industry report. Rea...
Eli Lilly: Jardiance Improves Overall Blood Sugar Control In Children With Type 2 Diabetes
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) said the DINAMO phase III clinical trial met its primary endpoint by showing a statistically significant...